Clinical Trials Logo

Kidney Graft Dysfunction clinical trials

View clinical trials related to Kidney Graft Dysfunction.

Filter by:
  • None
  • Page 1

NCT ID: NCT03155763 Completed - Clinical trials for Kidney Graft Dysfunction

Histology of Implantation Biopsies and Kidney Allograft Outcomes

KALIMBO
Start date: April 1, 2005
Phase: N/A
Study type: Observational

The morphology of transplanted kidney is considered to be important for graft outcomes in early and late posttransplant period. Individual histological lesions at the time of kidney transplantation, such as sclerosis of glomeruli, vascular narrowing and interstitial fibrosis, and composite histological lesions, which integrate histopathological findings in different compartments, showed association with suboptimal graft outcomes. However there are no consistent association between individual or composite lesions and transplant outcomes. Some possible explanations for such inconsistent results are non-uniformity in grading histological lesions or in defining graft outcomes. Furthermore, studies vary in terms of patient selection, and some results are not corrected for covariates. It is also unclear, whether acute biopsy features associated with the donor kidney can provide prognostic information, in addition to the chronic lesions? This single-center study aimed to evaluate which acute and chronic histological lesions and composite histological scores in donor kidney intraoperative biopsies alone or in combination with clinical variables are best associated with short- and long-term kidney graft outcomes, such as impairment of early kidney allograft function, immunological acute kidney allograft rejection, pyelonephritis, allograft function at 1, 3, 6, 12 months, 2, 3, 4 and 5 years, and graft survival at 1 and 5 years.

NCT ID: NCT01492894 Withdrawn - Clinical trials for Kidney Graft Dysfunction

Kidney Allograft Dysfunction Without Reversible Causes

KADWORC
Start date: January 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn the best way to prolong kidney life in patients exposed to calcineurin inhibitors, who already have evidence of damage possibly caused by the calcineurin inhibitor on kidney biopsy.